Moleculin Biotech Inc (MBRX)

NASDAQ
Currency in USD
1.060
-0.050(-4.50%)
Closed·
Pre Market
1.051-0.009(-0.85%)
·
MBRX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
1.0301.100
52 wk Range
0.3985.470
Key Statistics
Edit
Prev. Close
1.06
Open
1.1
Day's Range
1.03-1.1
52 wk Range
0.398-5.47
Volume
256.49K
Average Volume (3m)
5.6M
1-Year Change
-77.11%
Book Value / Share
1.99
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MBRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
10.667
Upside
+906.29%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Moleculin Biotech Company Profile

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 3 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Moleculin Biotech Inc Earnings Call Summary for Q4/2024

  • Moleculin launching Phase 3 trial for Anamycin, targeting AML; first patient enrollment expected Q1 2025
  • Cash balance of $13M, sufficient until Q3 2025; operating expenses reduced by $3M in 2024
  • Stock price fell 3.66% to $1.09; market cap at $16.2M with 14M shares outstanding
  • Estimated trial costs $60-70M; cash burn projected at $5M/quarter in 2025, rising to $7-8M in 2026
  • CEO highlights Anamycin's potential as first non-cardiotoxic anthracycline; CMO confirms safety in unfit patients
Last Updated: 24-03-2025, 08:40 pm
Read Full Transcript

Compare MBRX to Peers and Sector

Metrics to compare
MBRX
Peers
Sector
Relationship
P/E Ratio
−0.7x−0.5x−0.5x
PEG Ratio
−0.010.000.00
Price/Book
2.5x1.0x2.6x
Price / LTM Sales
-12.2x2.9x
Upside (Analyst Target)
-230.6%57.1%
Fair Value Upside
Unlock11.4%9.0%Unlock

Analyst Ratings

2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 10.667
(+906.29% Upside)

Earnings

Latest Release
May 09, 2024
EPS / Forecast
-- / -2.78
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Moleculin Biotech (MBRX) Stock Price Today?

The Moleculin Biotech stock price today is 1.06.

What Stock Exchange Does Moleculin Biotech Trade On?

Moleculin Biotech is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Moleculin Biotech?

The stock symbol for Moleculin Biotech is "MBRX."

What Is the Moleculin Biotech Market Cap?

As of today, Moleculin Biotech market cap is 14.84M.

What is Moleculin Biotech Earnings Per Share?

The Moleculin Biotech EPS is -6.32.

From a Technical Analysis Perspective, Is MBRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.